Results 21 to 30 of about 171,246 (253)
Antioxidants, 2021 Hepatotoxicity caused by chemotherapeutic drugs (e.g., doxorubicin) is of critical concern in cancer therapy. This study focused on investigating the modulatory effects of diosmin against doxorubicin-induced hepatotoxicity in Male Wistar rats.
Abdullah F. AlAsmari +11 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Doxorubicin‐induced myocardial injury is reflected by the presence of vacuolization in both clinical and animal models. The lack of scar tissue to replace the vacuolizated cardiomyocytes indicates that insufficient cardiac inflammation and ...
Guiwen Xu +6 more
doaj +1 more source
A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity.
PLoS Computational Biology, 2011 Although doxorubicin toxicity in cancer cells is multifactorial, the enzymatic bioactivation of the drug can significantly contribute to its cytotoxicity. Previous research has identified most of the components that comprise the doxorubicin bioactivation
Nnenna A Finn +2 more
doaj +1 more source
Acta Pharmaceutica Sinica B, 2023 Since the utilization of anthracyclines in cancer therapy, severe cardiotoxicity has become a major obstacle. The major challenge in treating cancer patients with anthracyclines is minimizing cardiotoxicity without compromising antitumor efficacy. Herein,
Kezheng Peng +10 more
doaj +1 more source
Cells, 2018 This study aimed to examine the effect of lipid emulsion on the cardiotoxicity induced by doxorubicin in H9c2 rat cardiomyoblasts and elucidates the associated cellular mechanism.
Raghavendra Baregundi Subbarao +6 more
doaj +1 more source
PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
Current Problems in Cancer: Case Reports, 2020 Drug induced pancreatitis is rare and establishing the exact causal relationship is challenging. Here, we discuss the management of a 60 year-old female patient with stage 3a breast cancer who developed doxorubicin induced pancreatitis 3 days after her ...
Luke Ardolino, Eugene Moylan
doaj +1 more source
BMC Cancer, 2018 Background Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes.
William P. McGuire +6 more
doaj +1 more source
Cardio-Oncology, 2020 Background Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity.
Jieli Li +7 more
doaj +1 more source
Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation
BMC Cancer, 2008 Background Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells.
Zhou Chun-lei +9 more
doaj +1 more source
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. [PDF]
PLoS ONE, 2015 Doxorubicin has been shown to inhibit proliferation of cancer cells through proteolytic activation of CREB3L1 (cAMP response element binding protein 3-like 1), a transcription factor synthesized as a membrane-bound precursor.
Bray Denard +7 more
doaj +1 more source